PPA
TVRD

Parametric Portfolio Associates’s Tvardi Therapeutics TVRD Stock Holding History

Parametric Portfolio Associates’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.09M Sell
2,492
-965
-28% -$396K ﹤0.01% 2743
2021
Q4 		$1.52M Sell
3,457
-1,800
-34% -$904K ﹤0.01% 2606
2021
Q3 		$2.92M Buy
5,257
+1,870
+55% +$938K ﹤0.01% 2181
2021
Q2 		$1.74M Buy
3,387
+1,739
+106% +$1.1M ﹤0.01% 2509
2021
Q1 		$1.29M Buy
1,648
+199
+14% +$136K ﹤0.01% 3038
2020
Q4 		$789K Sell
1,449
-892
-38% -$468K ﹤0.01% 3168
2020
Q3 		$1.07M Sell
2,341
-4
-0.2% -$2.32K ﹤0.01% 2887
2020
Q2 		$1.44M Buy
2,345
+556
+31% +$307K ﹤0.01% 2709
2020
Q1 		$851K Buy
1,789
+469
+36% +$255K ﹤0.01% 2881
2019
Q4 		$766K Sell
1,320
-1,019
-44% -$715K ﹤0.01% 3195
2019
Q3 		$1.54M Buy
2,339
+1,414
+153% +$1.18M ﹤0.01% 2800
2019
Q2 		$716K Buy
925
+19
+2% +$13.3K ﹤0.01% 3211
2019
Q1 		$640K Sell
906
-85
-9% -$50.9K ﹤0.01% 3226
2018
Q4 		$464K Buy
991
+59
+6% +$38.1K ﹤0.01% 3347
2018
Q3 		$803K Sell
932
-61
-6% -$44K ﹤0.01% 3214
2018
Q2 		$685K Buy
993
+6
+0.6% +$3.05K ﹤0.01% 3219
2018
Q1 		$440K Sell
987
-19
-2% -$9.22K ﹤0.01% 3407
2017
Q4 		$443K Buy
1,006
+75
+8% +$34.2K ﹤0.01% 3392
2017
Q3 		$459K Sell
931
-1,435
-61% -$719K ﹤0.01% 3467
2017
Q2 		$1.31M Sell
2,366
-383
-14% -$243K ﹤0.01% 2821
2017
Q1 		$1.82M Buy
2,749
+1,146
+71% +$612K ﹤0.01% 2505
2016
Q4 		$536K Buy
+1,603
New +$514K ﹤0.01% 3151

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Parametric Portfolio Associates's TVRD Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Tvardi Therapeutics (TVRD) stake by 28% in Q1 2022, selling an estimated $396K and leaving 2,492 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2743.

Parametric Portfolio Associates first reported a position in TVRD in Q4 2016 and has held it in 22 quarters since. The position peaked at $2.92M in Q3 2021. 183 funds tracked by Wall St. Rank hold TVRD as of Q1 2022.

  • Parametric Portfolio Associates held 2,492 shares of Tvardi Therapeutics worth $1.09M as of Q1 2022.
  • Parametric Portfolio Associates sold 965 Tvardi Therapeutics shares in Q1 2022, an estimated $396K.
  • Tvardi Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2743 holding.
  • Parametric Portfolio Associates first reported a position in Tvardi Therapeutics in Q4 2016 and has held it in 22 quarters since.
  • Parametric Portfolio Associates's Tvardi Therapeutics position peaked at $2.92M in Q3 2021.
  • 183 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.